- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1750-1172
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Nintedanib in idiopathic and secondary pleuroparenchymal fibroelastosis ; volume:16 ; number:1 ; day:9 ; month:10 ; year:2021 ; pages:1-9 ; date:12.2021
Orphanet journal of rare diseases ; 16, Heft 1 (9.10.2021), 1-9, 12.2021
- Creator
-
Nasser, Mouhamad
Si-Mohamed, Salim
Turquier, Ségolène
Traclet, Julie
Ahmad, Kaïs
Philit, François
Bonniaud, Philippe
Chalabreysse, Lara
Thivolet-Béjui, Françoise
Cottin, Vincent
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13023-021-02043-5
- URN
-
urn:nbn:de:101:1-2021122519420492281087
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:27 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Nasser, Mouhamad
- Si-Mohamed, Salim
- Turquier, Ségolène
- Traclet, Julie
- Ahmad, Kaïs
- Philit, François
- Bonniaud, Philippe
- Chalabreysse, Lara
- Thivolet-Béjui, Françoise
- Cottin, Vincent
- SpringerLink (Online service)
Other Objects (12)
Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis
Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis
Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis
Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
Association between nintedanib adherence trajectory and healthcare use among idiopathic pulmonary fibrosis patients
Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Global Pharmacovigilance Data
Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis
Patient Profile-Based Management with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium
A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK
Efficacy and Safety of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis: An Update
Pirfenidone vs. nintedanib in patients with idiopathic pulmonary fibrosis: a retrospective cohort study
Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis
Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis
Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis
Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
Association between nintedanib adherence trajectory and healthcare use among idiopathic pulmonary fibrosis patients
Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Global Pharmacovigilance Data
Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis
Patient Profile-Based Management with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium
A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK
Efficacy and Safety of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis: An Update
Pirfenidone vs. nintedanib in patients with idiopathic pulmonary fibrosis: a retrospective cohort study
Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis
Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis
Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis
Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
Association between nintedanib adherence trajectory and healthcare use among idiopathic pulmonary fibrosis patients
Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Global Pharmacovigilance Data
Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis
Patient Profile-Based Management with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium
A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK
Efficacy and Safety of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis: An Update